Co-expression of CD40/CD40L On XG1 Multiple Myeloma Cells Promotes IL-6 Autocrine Function

REFERENCES

• Stevenson FK, Anderson KC. Preparing the ground for vaccination against multiple myeloma. Immunol Today 2000;21: 170–171.
   PubMedGoogle Scholar
• van Zaanen HC, Koopmans RP, Aarden LA, Rensink HJ, Stouthard JM, Warnaar SO, Lokhorst HM, van Oers MH. Endogenous interleukin 6 production in multiple myeloma patients treated with chimeric monoclonal anti-IL6 antibodies indicates the existence of a positive feed-back loop. J Clin Invest 1996;98:1441–1448.
   PubMed Web of Science ®Google Scholar
• Klein B, Zhang XG, Jourdan M, Content J, Houssiau F, Aarden L, Piechaczyk M, Bataille R. Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood 1989;73:517–526.
   PubMed Web of Science ®Google Scholar
• Westendorf JJ, Ahmann GJ, Armitage RJ, Spriggs MK, Lust JA, Greipp PR, Katzmann JA, Jelinek DF. CD40 expression in malignant plasma cells. Role in stimulation of autocrine IL-6 secretion by a human myeloma cell line. J Immunol 1994;152:117–128.
   PubMed Web of Science ®Google Scholar
• Lu ZY, Brochier J, Wijdenes J, Brailly H, Bataille R, Klein B. High amounts of circulating interleukin (IL)-6 in the form of monomeric immune complexes during anti-IL-6 therapy. Towards a new methodology for measuring overall cytokine production in human in vivo. Eur J Immunol 1992;22:2819–2824.
   PubMed Web of Science ®Google Scholar
• Urashima M, Chauhan D, Uchiyama H, Freeman GJ, Anderson KC. CD40 ligand triggered interleukin-6 secretion in multiple myeloma. Blood 1995;85:1903–1912.
   PubMed Web of Science ®Google Scholar
• Grewal IS, Flavell RA. CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol 1998;16:111–135.
   PubMed Web of Science ®Google Scholar
• Schonbeck U, Libby P. The CD40/CD154 receptor/ligand dyad. Cell Mol Life Sci 2001;58:4–43.
   PubMed Web of Science ®Google Scholar
• Guzman-Rojas L, Sims-Mourtada JC, Rangel R, Martinez-Valdez H. Life and death within germinal centres: a double-edged sword. Immunology 2002;107:167–175.
   PubMed Web of Science ®Google Scholar
• Kawamura T, Kanai T, Dohi T, Uraushihara K, Totsuka T, Iiyama R, Taneda C, Yamazaki M, Nakamura T, Higuchi T, Aiba Y, Tsubata T, Watanabe M. Ectopic CD40 ligand expression on B cells triggers intestinal inflammation. J Immunol 2004;172:6388–6397.
   PubMed Web of Science ®Google Scholar
• Grammer AC, McFarland RD, Heaney J, Darnell BF, Lipsky PE. Expression, regulation, and function of B cell-expressed CD154 in germinal centers. J Immunol 1999;163:4150–4159.
   PubMed Web of Science ®Google Scholar
• Clodi K, Asgary Z, Zhao S, Kliche KO, Cabanillas F, Andreeff M, Younes A. Coexpression of CD40 and CD40 ligand in B-cell lymphoma cells. Br J Haematol 1998;103:270–275.
   PubMed Web of Science ®Google Scholar
• Pham LV, Tamayo AT, Yoshimura LC, Lo P, Terry N, Reid PS, Ford RJ. A CD40 Signalosome anchored in lipid rafts leads to constitutive activation of NF-kappaB and autonomous cell growth in B cell lymphomas. Immunity 2002;16:37–50.
   PubMed Web of Science ®Google Scholar
• Kawano M, Hirano T, Matsuda T, Taga T, Horii Y, Iwato K, Asaoku H, Tang B, Tanabe O, Tanaka H, et al. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 1988;332:83–85.
   PubMed Web of Science ®Google Scholar
• Clark EA, Shu G. Association between IL-6 and CD40 signaling. IL-6 induces phosphorylation of CD40 receptors. J Immunol 1990;145:1400–1406.
   PubMed Web of Science ®Google Scholar
• Tong AW, Stone MJ. CD40 and the effect of anti-CD40-binding on human multiple myeloma clonogenicity. Leuk Lymphoma 1996;21:1–8.
   PubMed Web of Science ®Google Scholar
• Hideshima T, Chauhan D, Schlossman R, Richardson P, Anderson KC. The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications. Oncogene 2001;20:4519–4527.
   PubMed Web of Science ®Google Scholar
• Fan Y, Ge Y, Zhu H, Wang Y, Yang B, Zhuang Y, Ma H, Zhang X. Characterization and application of two novel monoclonal antibodies against CD40L: epitope and functional studies on cell membrane CD40L and studies on the origin of soluble serum CD40L. Tissue Antigens 2004;64:257–263.
   PubMed Web of Science ®Google Scholar
• Zhang XG, Gaillard JP, Robillard N, Lu ZY, Gu ZJ, Jourdan M, Boiron JM, Bataille R, Klein B. Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma. Blood 1994;83:3654–3663.
   PubMed Web of Science ®Google Scholar
• Tong AW, Seamour B, Chen J, Su D, Ordonez G, Frase L, Netto G, Stone MJ. CD40 ligand-induced apoptosis is Fas-independent in human multiple myeloma cells. Leuk Lymphoma 2000;36:543–558.
   PubMed Web of Science ®Google Scholar
• Li G, Diogo D, Wu D, Spoonamore J, Dancik V, Franke L, Kurreeman F, Rossin EJ, Duclos G, Hartland C, Zhou X, Li K, Liu J, De Jager PL, Siminovitch KA, Zhernakova A, Raychaudhuri S, Bowes J, Eyre S, Padyukov L, Gregersen PK, Worthington J; Rheumatoid Arthritis Consortium International (RACI), Gupta N, Clemons PA, Stahl E, Tolliday N, Plenge RM. Human genetics in rheumatoid arthritis guides a high-throughput drug screen of the CD40 signaling pathway. PLoS Genet 2013;9:e1003487.
   PubMed Web of Science ®Google Scholar
• Rahman MM, Kukita A, Kukita T, Shobuike T, Nakamura T, Kohashi O. Two histone deacetylase inhibitors, trichostatin A and sodium butyrate, suppress differentiation into osteoclasts but not into macrophages. Blood 2003;101:3451–3459.
   PubMed Web of Science ®Google Scholar
• Kim MM, Kudchadker RJ, Kanke JE, Zhang S, Perkins GH. Bolus electron conformal therapy for the treatment of recurrent inflammatory breast cancer: a case report. Med Dosim 2012;37: 208–213.
   PubMed Web of Science ®Google Scholar
• Jourdan M, Tarte K, Legouffe E, Brochier J, Rossi JF, Klein B. Tumor necrosis factor is a survival and proliferation factor for human myeloma cells. Eur Cytokine Netw 1999;10:65–70.
   PubMed Web of Science ®Google Scholar
• Bradley JR, Pober JS. Tumor necrosis factor receptor-associated factors (TRAFs). Oncogene 2001;20:6482–6491.
   PubMedGoogle Scholar
• Wykes M. Why do B cells produce CD40 ligand? Immunol Cell Biol 2003;81:328–331.
   PubMed Web of Science ®Google Scholar
• Karin M, Lin A. NF-kappaB at the crossroads of life and death. Nat Immunol 2002;3:221–227.
   PubMed Web of Science ®Google Scholar
• Arron JR, Pewzner-Jung Y, Walsh MC, Kobayashi T, Choi Y. Regulation of the subcellular localization of tumor necrosis factor receptor-associated factor (TRAF)2 by TRAF1 reveals mechanisms of TRAF2 signaling. J Exp Med 2002;196:923–934.
   PubMed Web of Science ®Google Scholar
• Jourdan M, Zhang XG, Portier M, Boiron JM, Bataille R, Klein B. IFN-alpha induces autocrine production of IL-6 in myeloma cell lines. J Immunol. 1991;147:4402–7.
   PubMed Web of Science ®Google Scholar
• Jalukar SV, Hostager BS, Bishop GA. Characterization of the roles of TNF receptor-associated factor 6 in CD40-mediated B lymphocyte effector functions. J Immunol 2000;164:623–630.
   PubMed Web of Science ®Google Scholar
• Lee HH, Dempsey PW, Parks TP, Zhu X, Baltimore D, Cheng G. Specificities of CD40 signaling: involvement of TRAF2 in CD40-induced NF-kappaB activation and intercellular adhesion molecule-1 up-regulation. Proc Natl Acad Sci U S A 1999;96:1421–1426.
   PubMed Web of Science ®Google Scholar
• Werneburg BG, Zoog SJ, Dang TT, Kehry MR, Crute JJ. Molecular characterization of CD40 signaling intermediates. J Biol Chem 2001;276:43334–43342.
   PubMed Web of Science ®Google Scholar
• Tai YT, Li X, Tong X, Santos D, Otsuki T, Catley L, Tournilhac O, Podar K, Hideshima T, Schlossman R, Richardson P, Munshi NC, Luqman M, Anderson KC. Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma. Cancer Res 2005;65:5898–5906.
   PubMed Web of Science ®Google Scholar
• Law CL, Gordon KA, Collier J, Klussman K, McEarchern JA, Cerveny CG, Mixan BJ, Lee WP, Lin Z, Valdez P, Wahl AF, Grewal IS. Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40. Cancer Res 2005;65:8331–8338.
   PubMed Web of Science ®Google Scholar
• Tai YT, Li XF, Catley L, Coffey R, Breitkreutz I, Bae J, Song W, Podar K, Hideshima T, Chauhan D, Schlossman R, Richardson P, Treon SP, Grewal IS, Munshi NC, Anderson KC. Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications. Cancer Res 2005;65:11712–11720.
   PubMed Web of Science ®Google Scholar